Directed Phenotype Switching as an Effective Antimelanoma Strategy

Cancer Cell

Volumn 24, Issue 1, 2013, Pages 105-119

  Sáez Ayala, Magalí ^a   Montenegro, María F ^a   Sánchez del Campo, Luis ^b   Fernández Pérez, María Piedad ^a   Chazarra, Soledad ^a   Freter, Rasmus ^b   Middleton, Mark ^c   Piñero Madrona, Antonio ^d   Cabezas Herrera, Juan ^d   Goding, Colin R ^b   Rodríguez López, José Neptuno ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 O (3,4,5 TRIMETHOXYBENZOYL) (LEVO) EPICATECHIN; DIHYDROFOLATE REDUCTASE; EPICATECHIN; METHOTREXATE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; THYMIDINE; THYMIDINE TRIPHOSPHATE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL DIFFERENTIATION; CELL INVASION; CELL LINEAGE; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG SENSITIZATION; ENZYME INHIBITION; GENE EXPRESSION; GENE SWITCHING; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

EID: 84880044594     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.05.009     Document Type: Article

References (55)

1. Angus S.P., Wheeler L.J., Ranmal S.A., Zhang X., Markey M.P., Mathews C.K., Knudsen E.S. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J.Biol. Chem. 2002, 277:44376-44384.
2. Arnheiter H. The discovery of the microphthalmia locus and its gene, Mitf. Pigment Cell Melanoma Res. 2010, 23:729-735.
3. Bennett D.C. How to make a melanoma: what do we know of the primary clonal events?. Pigment Cell Melanoma Res. 2008, 21:27-38.
4. Blagosklonny M.V. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 2005, 4:1693-1698.
5. Box N.F., Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res. 2008, 21:525-533.
6. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5:744-749.
7. Carreira S., Goodall J., Aksan I., La Rocca S.A., Galibert M.D., Denat L., Larue L., Goding C.R. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005, 433:764-769.
8. Carreira S., Goodall J., Denat L., Rodriguez M., Nuciforo P., Hoek K.S., Testori A., Larue L., Goding C.R. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006, 20:3426-3439.
9. Cheli Y., Ohanna M., Ballotti R., Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 2010, 23:27-40.
10. Cheli Y., Giuliano S., Botton T., Rocchi S., Hofman V., Hofman P., Bahadoran P., Bertolotto C., Ballotti R. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011, 30:2307-2318.
11. Cheli Y., Giuliano S., Fenouille N., Allegra M., Hofman V., Hofman P., Bahadoran P., Lacour J.P., Tartare-Deckert S., Bertolotto C., Ballotti R. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 2012, 31:2461-2470.
12. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J.Clin. Oncol. 2006, 24:4340-4346.
13. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
14. Dobbelstein M., Strano S., Roth J., Blandino G. p73-induced apoptosis: a question of compartments and cooperation. Biochem. Biophys. Res. Commun. 2005, 331:688-693.
15. Du J., Miller A.J., Widlund H.R., Horstmann M.A., Ramaswamy S., Fisher D.E. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am. J. Pathol. 2003, 163:333-343.
16. Elledge R.M., Gray R., Mansour E., Yu Y., Clark G.M., Ravdin P., Osborne C.K., Gilchrist K., Davidson N.E., Robert N., et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J.Natl. Cancer Inst. 1995, 87:1254-1256.
17. Fedorenko I.V., Paraiso K.H., Smalley K.S. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem. Pharmacol. 2011, 82:201-209.
18. Fidler I.J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978, 38:2651-2660.
19. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
20. Goodall J., Carreira S., Denat L., Kobi D., Davidson I., Nuciforo P., Sturm R.A., Larue L., Goding C.R. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res. 2008, 68:7788-7794.
21. Hallstrom T.C., Mori S., Nevins J.R. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008, 13:11-22.
22. Hodgkinson C.A., Moore K.J., Nakayama A., Steingrímsson E., Copeland N.G., Jenkins N.A., Arnheiter H. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 1993, 74:395-404.
23. Hoek K.S., Goding C.R. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 2010, 23:746-759.
24. Kinner A., Wu W., Staudt C., Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008, 36:5678-5694.
25. Kobi D., Steunou A.L., Dembélé D., Legras S., Larue L., Nieto L., Davidson I. Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene. Pigment Cell Melanoma Res. 2010, 23:404-418.
26. Kontaki H., Talianidis I. Lysine methylation regulates E2F1-induced cell death. Mol. Cell 2010, 39:152-160.
27. Lee M., Goodall J., Verastegui C., Ballotti R., Goding C.R. Direct regulation of the Microphthalmia promoter by Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2. J.Biol. Chem. 2000, 275:37978-37983.
28. Lin W.C., Lin F.T., Nevins J.R. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001, 15:1833-1844.
29. Loercher A.E., Tank E.M., Delston R.B., Harbour J.W. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J.Cell Biol. 2005, 168:35-40.
30. Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res. 2011, 24:902-921.
31. Martínez-Balbás M.A., Bauer U.M., Nielsen S.J., Brehm A., Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J. 2000, 19:662-671.
32. Muñoz-Pinedo C., Oliver F.J., López-Rivas A. Apoptosis of haematopoietic cells upon thymidylate synthase inhibition is independent of p53 accumulation and CD95-CD95 ligand interaction. Biochem. J. 2001, 353:101-108.
33. Myers K., Gagou M.E., Zuazua-Villar P., Rodriguez R., Meuth M. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet. 2009, 5:e1000324.
34. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
35. Nikolaev S.I., Rimoldi D., Iseli C., Valsesia A., Robyr D., Gehrig C., Harshman K., Guipponi M., Bukach O., Zoete V., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 2012, 44:133-139.
36. Pardee A.B., Li C.J., Reddy G.P. Regulation in S phase by E2F. Cell Cycle 2004, 3:1091-1094.
37. Pinner S., Jordan P., Sharrock K., Bazley L., Collinson L., Marais R., Bonvin E., Goding C., Sahai E. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 2009, 69:7969-7977.
38. Rodriguez R., Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol. Biol. Cell 2006, 17:402-412.
39. Sáez-Ayala M., Fernández-Pérez M.P., Montenegro M.F., Sánchez-del-Campo L., Chazarra S., Piñero-Madrona A., Cabezas-Herrera J., Rodríguez-López J.N. Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp. Cell Res. 2012, 318:1146-1159.
40. Sánchez-del-Campo L., Otón F., Tárraga A., Cabezas-Herrera J., Chazarra S., Rodríguez-López J.N. Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate. J.Med. Chem. 2008, 51:2018-2026.
41. Sánchez-del-Campo L., Tárraga A., Montenegro M.F., Cabezas-Herrera J., Rodríguez-López J.N. Melanoma activation of 3-o-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase. Mol. Pharm. 2009, 6:883-894.
42. Sánchez-del-Campo L., Montenegro M.F., Cabezas-Herrera J., Rodríguez-López J.N. The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate. Pigment Cell Melanoma Res. 2009, 22:588-600.
43. Serafino A., Sinibaldi-Vallebona P., Lazzarino G., Tavazzi B., Rasi G., Pierimarchi P., Andreola F., Moroni G., Galvano G., Galvano F., Garaci E. Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside. FASEB J. 2004, 18:1940-1942.
44. Sidi S., Sanda T., Kennedy R.D., Hagen A.T., Jette C.A., Hoffmans R., Pascual J., Imamura S., Kishi S., Amatruda J.F., et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008, 133:864-877.
45. Smalley K.S., Flaherty K.T. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br. J. Cancer 2009, 100:431-435.
46. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N.Engl. J. Med. 2012, 366:707-714.
47. Strub T., Giuliano S., Ye T., Bonet C., Keime C., Kobi D., Le Gras S., Cormont M., Ballotti R., Bertolotto C., Davidson I. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 2011, 30:2319-2332.
48. Tachibana M., Takeda K., Nobukuni Y., Urabe K., Long J.E., Meyers K.A., Aaronson S.A., Miki T. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. Nat. Genet. 1996, 14:50-54.
49. Urist M., Tanaka T., Poyurovsky M.V., Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 2004, 18:3041-3054.
50. van Elsas A., Zerp S., van der Flier S., Krüse-Wolters M., Vacca A., Ruiter D.J., Schrier P. Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis. Recent Results Cancer Res. 1995, 139:57-67.
51. Van Raamsdonk C.D., Bezrookove V., Green G., Bauer J., Gaugler L., O'Brien J.M., Simpson E.M., Barsh G.S., Bastian B.C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602.
52. Villanueva J., Vultur A., Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011, 71:7137-7140.
53. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
54. Wang A., Li C.J., Reddy P.V., Pardee A.B. Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation. Cancer Res. 2005, 65:7809-7814.
55. Zaidi M.R., Davis S., Noonan F.P., Graff-Cherry C., Hawley T.S., Walker R.L., Feigenbaum L., Fuchs E., Lyakh L., Young H.A., et al. Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature 2011, 469:548-553.